Xilingio 10mg/5mg Tablet

This dual mechanism offers improved glycemic control by targeting both renal glucose handling and pancreatic hormone regulation. Xilingio is typically prescribed as adjunctive therapy to diet and exercise when monotherapy is insufficient. It may be used alone or in combination with other antidiabetic agents. The fixed-dose combination simplifies treatment regimens, potentially enhancing patient adherence.

Common adverse effects include urinary tract infections, nasopharyngitis, and hypoglycemia, particularly when used with insulin or sulfonylureas. Caution is advised in patients with renal impairment, and it is contraindicated in type 1 diabetes or diabetic ketoacidosis. Regular monitoring of renal function and blood glucose is recommended during therapy. Xilingio should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize risks.